You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 124 No. 5, May 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (8)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Costs of Posttreatment Surveillance for Patients With Upper Aerodigestive Tract Cancer

Katherine S. Virgo, PhD; Randal C. Paniello, MD; Frank E. Johnson, MD

Arch Otolaryngol Head Neck Surg. 1998;124:564-572.

Objectives  To determine the range of recommended follow-up strategies for patients with upper aerodigestive tract cancer treated with curative intent and to estimate the cost of follow-up.

Design  Economic analyses of the costs associated with 31 follow-up strategies (12 generic and 19 site specific) identified from a MEDLINE search of the literature for 1978 to 1997 and a search of major textbooks. Generic strategies are not specific for site or histology and are exclusive of strategies designed for the rare patient, ie, patients who would not be considered average in terms of clinical characteristics. Charge data obtained from the Part B Medicare Annual Data File and the Hospital Outpatient Bill File were used as a proxy for cost.

Setting  Ambulatory care.

Main Outcome Measures  Nationwide Medicare-allowed charges and an actual-charge proxy for 5 years of surveillance after treatment for upper aerodigestive tract cancer.

Results  Medicare-allowed charges for 5-year follow-up ranged from a low of $739 to a high of $14079 for the generic and site-specific strategies combined and from $739 to $4646 for the 12 generic strategies alone. When Medicare-allowed charges were converted to a proxy for actual charges using a conversion ratio of 1.62, the range was $1198 to $22807 for all strategies combined (a 19-fold difference in charges) and $1198 to $7597 for the generic strategies alone (a 5-fold difference in charges).

Conclusions  Charges vary extensively across surveillance strategies, particularly if site-specific strategies are considered, although the potential benefit of more intensive, higher-cost strategies on survival or quality of life has yet to be demonstrated.


From the Department of Surgery, St Louis University Health Sciences Center (Drs Virgo and Johnson), Surgical Service, St Louis Department of Veterans Affairs Medical Center (Drs Paniello and Johnson), and Department of Otolaryngology, Washington University School of Medicine (Dr Paniello), St Louis, Mo.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Geographical Variation in Surveillance Strategies After Curative-Intent Surgery for Upper Aerodigestive Tract Cancer
Johnson et al.
Ann. Surg. Oncol. 2006;13:1063-1071.
ABSTRACT | FULL TEXT  

Effective health care: management of head and neck cancers
Collins et al.
Qual Saf Health Care 2005;14:144-148.
ABSTRACT | FULL TEXT  

Practice Patterns and Clinical Guidelines for Posttreatment Follow-up of Head and Neck Cancers: A Comparison of 2 Professional Societies
Paniello et al.
Arch Otolaryngol Head Neck Surg 1999;125:309-313.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.